AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Neutra Corp.

$0 +$0.00 (+50.00%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0 - $0
Year Range
$0$0
Market Cap
437.69K
AVG Volume
1.27M
Trailing/Forward PE
1.5/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD) · TTM
0500K1M1.5M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
27 Q11.18M
26 Q41.02M
26 Q3824.45K
26 Q2481.18K
26 Q1235.76K
25 Q468.06K
25 Q395.16K
25 Q287.91K
25 Q166.07K
24 Q439.53K
Net Income (USD) · TTM
-2M-1M01M2M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
27 Q11.03M
26 Q4-6.94K
26 Q3-1.31M
26 Q2-990.22K
26 Q1-1.04M
25 Q4-109.02K
25 Q3-108.3K
25 Q2-138.56K
25 Q1-177.82K
24 Q4-233.47K
Operating Income (USD) · TTM
-1M01M2M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
27 Q11.1M
26 Q487.49K
26 Q3-783.47K
26 Q2-936.33K
26 Q1-990.04K
25 Q4-105.42K
25 Q3-104.75K
25 Q2-133.7K
25 Q1-173.76K
24 Q4-229.49K
EBITDA (USD) · TTM
-1M01M2M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
27 Q11.11M
26 Q492.56K
26 Q3-780.19K
26 Q2-934.37K
26 Q1-989.36K
25 Q4-104.35K
25 Q3-97.26K
25 Q2-117.1K
25 Q1-144.13K
24 Q4-181.25K
Cash Flows (USD) · TTM
-400K-200K0200K23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q126 Q427 Q1
NTRR Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
27 Q173.52K
26 Q434.15K
25 Q1-2.81K
24 Q4-10.34K
24 Q3-9.76K
24 Q2-32.55K
24 Q1-69.41K
23 Q4-153.24K
23 Q3-207.76K
23 Q2-333.09K
EPS (USD) · TTM
-0-0-0-0024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
27 Q10
26 Q4-0
26 Q3-0
26 Q2-0
26 Q1-0
25 Q40
25 Q30
25 Q20
25 Q1-0
24 Q4-0
Expenses (USD) · TTM
-500K0500K1M1.5MSG&ACapex24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
24 Q30
24 Q20
24 Q10
23 Q40
23 Q30
23 Q20
27 Q1595.22K
26 Q41.38M
26 Q31.23M
26 Q21.15M
26 Q11.07M
25 Q4168.66K
25 Q3170.65K
25 Q2183.14K
25 Q1186.62K
24 Q4195.58K
Shares Outstanding · TTM
00.250.50.75123 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q126 Q427 Q1
NTRR Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
27 Q10
26 Q40
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
23 Q40
23 Q30
23 Q20
Employee Count
0510152020212022
NTRR Employee Count by quarter
PeriodEmployee Count
202215
202115
PE Ratio
0.20.40.60.8med 0.37Oct 16Dec 16Jan 17Feb 17Apr 17Jul 26Sep 26
NTRR PE Ratio by quarter
PeriodPE Ratio
Sep 260.43
Sep 260.28
Aug 260.43
Aug 260.28
Aug 260.28
Aug 260.57
Jul 260.28
May 170.2
May 170.21
Apr 170.25
Apr 170.28
Apr 170.3
Apr 170.26
Mar 170.29
Mar 170.35
Mar 170.33
Mar 170.33
Mar 170.37
Feb 170.55
Feb 170.52
Feb 170.38
Feb 170.57
Jan 170.6
Jan 170.59
Jan 170.42
Jan 170.46
Dec 160.37
Dec 160.31
Dec 160.27
Dec 160.3
Dec 160.34
Nov 160.43
Nov 160.49
Nov 160.53
Nov 160.53
Oct 160.53
Oct 160.69
Free Cash Flow Yield
-60%-40%-20%0%20%40%med -1.12%Jun 23Oct 23Jan 24May 24Aug 24May 26Sep 26
NTRR Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 2616.8%
Sep 2625.2%
Aug 2616.8%
Aug 2625.2%
Aug 2625.2%
Aug 2612.6%
Jul 2625.2%
Jul 2611.22%
Jul 2611.22%
Jul 2611.22%
Jul 265.61%
Jun 265.61%
Jun 2611.22%
Jun 2611.22%
Jun 2611.22%
May 2611.22%
May 267.48%
May 267.48%
May 267.48%
May 2611.22%
Oct 24-0.96%
Oct 24-0.96%
Oct 24-0.96%
Oct 24-0.48%
Sep 24-0.48%
Sep 24-0.96%
Sep 24-0.96%
Sep 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-1.77%
Jul 24-1.34%
Jul 24-1.34%
Jul 24-1.34%
Jul 24-1.34%
Jun 24-1.67%
Jun 24-1.34%
Jun 24-1.12%
Jun 24-1.67%
May 24-1.12%
May 24-1.12%
May 24-1.12%
May 24-1.12%
May 24-0.84%
Apr 24-1.67%
Apr 24-0.84%
Apr 24-0.84%
Apr 24-1.12%
Mar 24-1.12%
Mar 24-1.12%
Mar 24-0.96%
Mar 24-1.12%
Mar 24-0.96%
Feb 24-1.12%
Feb 24-0.84%
Feb 24-1.12%
Feb 24-1.29%
Jan 24-1.12%
Jan 24-1.34%
Jan 24-1.34%
Jan 24-1.12%
Dec 23-1.12%
Dec 23-1.12%
Dec 23-0.84%
Dec 23-3.72%
Dec 23-3.72%
Nov 23-3.72%
Nov 23-3.19%
Nov 23-3.19%
Nov 23-2.79%
Oct 23-3.72%
Oct 23-3.72%
Oct 23-3.72%
Oct 23-2.79%
Sep 23-2.23%
Sep 23-2.79%
Sep 23-2.79%
Sep 23-4.77%
Sep 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Jul 23-3.97%
Jul 23-4.77%
Jul 23-5.96%
Jul 23-6.81%
Jun 23-4.77%
Jun 23-3.97%
Jun 23-11.17%
Jun 23-9.31%
Jun 23-30.1%
May 23-22.58%
May 23-22.58%
May 23-45.15%
May 23-22.58%
Apr 23-30.1%
Apr 23-22.58%
Price to Sales
051015med 2.48Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NTRR Price to Sales by quarter
PeriodPrice to Sales
Sep 260.37
Sep 260.25
Aug 260.37
Aug 260.25
Aug 260.25
Aug 260.5
Jul 260.25
Jul 260.3
Jul 260.3
Jul 260.3
Jul 260.59
Jun 260.59
Jun 260.3
Jun 260.3
Jun 260.3
May 260.3
May 260.45
May 260.45
May 260.45
May 260.3
Apr 260.25
Apr 260.25
Apr 260.5
Apr 260.38
Mar 260.25
Mar 260.38
Mar 260.5
Mar 260.5
Feb 260.25
Feb 260.5
Feb 260.25
Feb 260.5
Jan 260.5
Jan 260.91
Jan 261.21
Jan 260.61
Jan 260.61
Dec 251.21
Dec 251.21
Dec 251.21
Dec 250.61
Nov 251.21
Nov 250.61
Nov 250.61
Nov 251.82
Oct 251.21
Oct 253.71
Oct 252.48
Oct 252.48
Oct 251.24
Sep 253.71
Sep 253.71
Sep 252.48
Sep 252.48
Aug 252.48
Aug 252.48
Aug 251.24
Aug 252.48
Aug 251.24
Jul 258.57
Jul 258.57
Jul 2512.86
Jul 2512.86
Jun 254.29
Jun 254.29
Jun 256.43
Jun 258.57
May 254.29
May 254.29
May 258.57
May 258.57
May 2512.86
Apr 256.13
Apr 256.13
Apr 259.2
Apr 256.13
Mar 259.2
Mar 256.13
Mar 256.13
Mar 259.2
Feb 256.13
Feb 253.07
Feb 256.13
Feb 256.13
Jan 256.13
Jan 256.64
Jan 259.96
Jan 259.96
Jan 258.3
Dec 246.64
Dec 249.96
Dec 246.64
Dec 246.64
Nov 243.32
Nov 243.32
Nov 243.32
Nov 243.32
Nov 243.32
Oct 244.42
Oct 244.42
EV/EBITDA
02468med 0.69Oct 16Dec 16Feb 17Apr 17May 26Jul 26Sep 26
NTRR EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 260.45
Sep 260.32
Aug 260.45
Aug 260.32
Aug 260.32
Aug 260.58
Jul 260.32
Jul 263.89
Jul 263.89
Jul 263.89
Jul 267.18
Jun 267.18
Jun 263.89
Jun 263.89
Jun 263.89
May 263.89
May 265.53
May 265.53
May 265.53
May 263.89
May 170.37
May 170.39
Apr 170.45
Apr 170.49
Apr 170.52
Apr 170.45
Mar 170.5
Mar 170.59
Mar 170.56
Mar 170.56
Mar 170.61
Feb 170.89
Feb 170.84
Feb 170.63
Feb 170.91
Jan 170.97
Jan 170.95
Jan 170.69
Jan 170.75
Dec 160.61
Dec 160.52
Dec 160.46
Dec 160.5
Dec 160.57
Nov 160.7
Nov 160.79
Nov 160.85
Nov 160.86
Oct 160.86
Oct 161.09
Price/Operating Cashflow
05101520med 8.91May 26May 26Jun 26Jul 26Jul 26Aug 26Sep 26
NTRR Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 266.22
Sep 264.14
Aug 266.22
Aug 264.14
Aug 264.14
Aug 268.29
Jul 264.14
Jul 268.91
Jul 268.91
Jul 268.91
Jul 2617.82
Jun 2617.82
Jun 268.91
Jun 268.91
Jun 268.91
May 268.91
May 2613.36
May 2613.36
May 2613.36
May 268.91
Neutra Corp.
NTRR
Stockpicker

Video analysis: NTRR

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NTRR

Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network

globenewswire.com · 14 Sep 2026

Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) subsidiary, Neutra Life Sciences (“NLS”), has expanded its 2026 industry conference schedule with the addition of three new events — Partnership with Sites, DPharm: Disruptive Innovations to Advance Clinical Trials, and Fall Clinical – Dermatology — as part of its ongoing strategy to deepen sponsor and CRO relationships and expand trial opportunities across its growing site network.

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

globenewswire.com · 13 Jul 2026

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, centered on deepening relationships with clinical trial sponsors and Contract Research Organizations (CROs). Neutra Corp has committed its full resources to the growth and expansion of Neutra Life Sciences, its wholly owned clinical research Site Management Organization (SMO) subsidiary, as the Company's primary strategic priority for the remainder of 2026 and beyond.

Neutra Corp's Subsidiary Neutra Life Sciences Executes New Women's Health Joint Venture and Expands Trial Portfolio

globenewswire.com · 29 Jun 2026

Neutra Corp's Subsidiary Neutra Life Sciences Executes New Women's Health Joint Venture and Expands Trial Portfolio

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.